These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 37562536)
1. Neuroimmune Mechanisms of Opioid Use Disorder and Recovery: Translatability to Human Studies, and Future Research Directions. Butelman ER; Goldstein RZ; Nwaneshiudu CA; Girdhar K; Roussos P; Russo SJ; Alia-Klein N Neuroscience; 2023 Sep; 528():102-116. PubMed ID: 37562536 [TBL] [Abstract][Full Text] [Related]
2. Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review. Toloff K; Woodcock EA Med Res Arch; 2022 Aug; 10(8):. PubMed ID: 37744743 [TBL] [Abstract][Full Text] [Related]
3. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578 [TBL] [Abstract][Full Text] [Related]
4. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Moningka H; Lichenstein S; Worhunsky PD; DeVito EE; Scheinost D; Yip SW Neuropsychopharmacology; 2019 Jan; 44(2):259-273. PubMed ID: 30283002 [TBL] [Abstract][Full Text] [Related]
5. Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis. Daniulaityte R; Nahhas RW; Silverstein S; Martins S; Carlson RG J Subst Use Addict Treat; 2023 Apr; 147():208973. PubMed ID: 36804351 [TBL] [Abstract][Full Text] [Related]
6. Attenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys. Gerak LR; France CP J Pharmacol Exp Ther; 2023 Mar; 384(3):363-371. PubMed ID: 36575032 [TBL] [Abstract][Full Text] [Related]
8. Protracted abstinence in males with an opioid use disorder: partial recovery of nucleus accumbens function. Tolomeo S; Baldacchino A; Volkow ND; Steele JD Transl Psychiatry; 2022 Feb; 12(1):81. PubMed ID: 35217657 [TBL] [Abstract][Full Text] [Related]
9. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. Zhu Y; Evans EA; Mooney LJ; Saxon AJ; Kelleghan A; Yoo C; Hser YI J Neuroimmune Pharmacol; 2018 Dec; 13(4):488-497. PubMed ID: 30094695 [TBL] [Abstract][Full Text] [Related]
10. Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery. Cole S; Wirkus S Bull Math Biol; 2022 Mar; 84(4):48. PubMed ID: 35237877 [TBL] [Abstract][Full Text] [Related]
11. Sleep disturbance as a therapeutic target to improve opioid use disorder treatment. Huhn AS; Finan PH Exp Clin Psychopharmacol; 2022 Dec; 30(6):1024-1035. PubMed ID: 34110889 [TBL] [Abstract][Full Text] [Related]
12. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States. Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362 [TBL] [Abstract][Full Text] [Related]
13. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management. Pergolizzi JV; Raffa RB; Rosenblatt MH J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228 [TBL] [Abstract][Full Text] [Related]
14. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. Dunn KE; Huhn AS; Bergeria CL; Gipson CD; Weerts EM J Pharmacol Exp Ther; 2019 Nov; 371(2):422-452. PubMed ID: 31391211 [TBL] [Abstract][Full Text] [Related]
15. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. Yedinak JL; Goedel WC; Paull K; Lebeau R; Krieger MS; Thompson C; Buchanan AL; Coderre T; Boss R; Rich JD; Marshall BDL PLoS Med; 2019 Nov; 16(11):e1002963. PubMed ID: 31743335 [TBL] [Abstract][Full Text] [Related]
16. Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl. Spadaro A; Sarker A; Hogg-Bremer W; Love JS; O'Donnell N; Nelson LS; Perrone J Clin Toxicol (Phila); 2022 Jun; 60(6):694-701. PubMed ID: 35119337 [TBL] [Abstract][Full Text] [Related]
17. Medications for management of opioid use disorder. Koehl JL; Zimmerman DE; Bridgeman PJ Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869 [TBL] [Abstract][Full Text] [Related]
18. Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review. Englander H; Thakrar AP; Bagley SM; Rolley T; Dong K; Hyshka E JAMA Intern Med; 2024 Jun; 184(6):691-701. PubMed ID: 38683591 [TBL] [Abstract][Full Text] [Related]
19. Recovery from opioid use disorder: A 4-year post-clinical trial outcomes study. Craft WH; Tegge AN; Keith DR; Shin H; Williams J; Athamneh LN; Stein JS; Chilcoat HD; Le Moigne A; DeVeaugh-Geiss A; Bickel WK Drug Alcohol Depend; 2022 May; 234():109389. PubMed ID: 35287034 [TBL] [Abstract][Full Text] [Related]
20. Opioid Use Disorder among Hospitalized Adults in North Carolina: Analysis from the 2000-2020 NC State Inpatient Database. Alemu BT; Beydoun HA; Olayinka O; Harmer B; Brown AR South Med J; 2024 May; 117(5):226-234. PubMed ID: 38701842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]